Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Geron Corp (NASDAQ: GERN) | Delayed: 1.13 -0.03 (2.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.16 | 52 Week High | $5.30 | |||
| Open | $1.16 | 52 Week Low | $1.81 | |||
| Day High | $1.19 | P/E | N/A | |||
| Day Low | $1.12 | EPS | $-0.35 | |||
| Volume | 7,178,602 | |||||
